This finding was somewhat unexpected, however it is consistent with accumulating data from in vitro models showing that PI3K inhibitors can disrupt B-CLL-stromal interactions and with mouse models showing that p110δ inhibition can release marginal zone B cells from the spleen. The gene discussed is PIK3CD; the disease is B-cell chronic lymphocytic leukemia.